in this issue
People & Business :: Emerging Companies
'Humbled' Amyris Scales Back Expansions Plans
2:45 PM MST | February 16, 2012 | Rebecca Coons
Synthetic biology firm Amyris (Emeryville, CA) says operational challenges have forced it to re-evalutate its commercialization strategy and scale back ambitious 2012 production targets for biobased farnesene. The company will focus on higher-value opportunities in specialty chemicals for the versatile C15 hydrocarbon, leaving higher-volume base oils and biofuels efforts under previously-established joint ventures with Total and Cosan. “2011 was a year of accomplishment and a year of learning, says CEO John Melo. Amyris opened three...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee